指南与共识呼吸道感染

TSANZ关于澳大利亚和新西兰儿童、青少年及成人慢性化脓性肺疾病与支气管扩张的立场声明

Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.
指南 / 共识 · Respirology · 2023-03-02

该立场声明由多学科团队基于系统文献检索更新2015年指南,针对澳大利亚和新西兰慢性化脓性肺疾病(CSLD)和支气管扩张患者。主要建议包括早期诊断、CT确诊、个体化多学科管理、14天抗生素疗程治疗急性加重、根除铜绿假单胞菌及6个月监测等。

要点

  • 早期诊断CSLD和支气管扩张,注意与其他呼吸疾病共存。
  • 儿童支气管扩张需用年龄适配的CT方案和标准确诊。
  • 急性加重用14天抗生素疗程,依据培养和药敏结果。

核心结论

  • 早期诊断和个体化多学科管理可改善CSLD和支气管扩张患者的预后。

研究设计与样本

  • 多学科团队(含消费者)通过系统文献检索更新2015年指南形成的立场声明。

主要发现

  • 需早期诊断CSLD和支气管扩张,并注意其与哮喘、慢阻肺等共存。
  • 儿童支气管扩张需用年龄适配的CT方案和标准确诊。
  • 急性加重应给予14天抗生素疗程,基于下呼吸道培养和药敏结果。
  • 新检出铜绿假单胞菌应进行根除治疗。
  • 每6个月监测并发症和共病。

关键数值与推荐

  • 急性加重抗生素疗程为14天。
  • 每6个月监测并发症和共病。
  • 儿童CT确诊需使用年龄适配的方案和标准。

临床怎么用

  • 制定个体化多学科管理计划,协调医疗提供者间的照护。
  • 由呼吸物理治疗师教授气道清除技术,鼓励运动、优化营养、避免空气污染并按国家计划接种疫苗。
  • 重症或门诊治疗无反应者住院接受静脉抗生素和强化气道清除治疗。
  • 长期抗生素、吸入糖皮质激素、支气管舒张剂和黏液活性剂应个体化使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a multi-disciplinary team that included consumers. The main statements are: Diagnose CSLD and bronchiectasis early; this requires awareness of bronchiectasis symptoms and its co-existence with other respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease). Confirm bronchiectasis with a chest computed-tomography scan, using age-appropriate protocols and criteria in children. Undertake a baseline panel of investigations. Assess baseline severity, and health impact, and develop individualized management plans that include a multi-disciplinary approach and coordinated care between healthcare providers. Employ intensive treatment to improve symptom control, reduce exacerbation frequency, preserve lung function, optimize quality-of-life and enhance survival. In children, treatment also aims to optimize lung growth and, when possible, reverse bronchiectasis. Individualize airway clearance techniques (ACTs) taught by respiratory physiotherapists, encourage regular exercise, optimize nutrition, avoid air pollutants and administer vaccines following national schedules. Treat exacerbations with 14-day antibiotic courses based upon lower airway culture results, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients with severe exacerbations and/or not responding to outpatient therapy are hospitalized for further treatments, including intravenous antibiotics and intensive ACTs. Eradicate Pseudomonas aeruginosa when newly detected in lower airway cultures. Individualize therapy for long-term antibiotics, inhaled corticosteroids, bronchodilators and mucoactive agents. Ensure ongoing care with 6-monthly monitoring for complications and co-morbidities. Undertake optimal care of under-served peoples, and despite its challenges, delivering best-practice treatment remains the overriding aim.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Chang AB, Bell SC, Byrnes CA, et al. Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand. Respirology. 2023. PMID: 36863703. doi:10.1111/resp.14479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。